Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

Kurata, Takeshi; Matsuo, Keitaro; Takada, Minoru; Kawahara, Mutsuto; Tsuji, Masahiro; Matsubara, Yutaka; Otani, Nagahiro; Matsuyama, Shigeki; Muraishi, Kenya; Fujita, Tatsuo; Ishikawa, Masato; Koyano, Keita; Okamoto, Isamu; Satoh, Taroh; Tamura, Kenji; Nakagawa, Kazuhiko; Fukuoka, Masahiro

doi:10.1097/01243894-200609000-00014

Cited by 6 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…response and stable disease rate, is an interesting endpoint. Although it may to some extent only reflect an indolent disease natural history, it has been accepted as a meaningful endpoint particularly after the use of molecularly targeted therapies [19,21]. Evidence exists that it correlates with overall survival but it remains unclear how much the agent itself is contributing to this clinical benefit.…”

Section: Discussionmentioning

confidence: 97%

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Although the overall objective response rate in previously treated patients given EGFR inhibitors is low, many patients achieve stable disease that can be associated with a survival benefit 23 . Multiple phase II studies 17,24-26 and a phase III randomized trial 22 identified a series of clinical parameters associated with clinical responsiveness.…”

Section: Discussionmentioning

confidence: 99%

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Abdelsalam¹

2009

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Introduction:To evaluate the efficacy and tolerability of gefitinib (Iressa (ZD 1839); Astrazeneca, Willington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small cell lung cancer (NSCLC). Materials and Methods: Patients with pretreated advanced NSCLC received gefitinib at a daily dose of 250 mg orally until disease progression. Patients included in this study all had measurable, locally advanced or metastatic NSCLC, pretreated with at least one line of platinum based chemotherapy. Results: From June 2004 to February 2006, 18 consecutive patients were enrolled onto the study, the overall disease control rate was 66.7% (partial response (PR), 11.1%; stable disease (SD) 55.6%), median TTP was 2.9 months (95% confidence interval 2.3 to 3.2 months) and median PFS was 3 months (95% confidence interval 2.4 to 3.6 months), median OS from start of gefitinib was 8.4 months (95% confidence interval 5 to 11.8 months). Univariete analysis of prognostic factors revealed that, response to gefitinib and longer duration of gefitinib treatment showed a better PFS, while only longer duration of gefitinib treatment showed a better OS. Conclusion: Gefitinib showed clinically meaningful anti-tumor activity and provided symptom relief as second and third line treatment in pre-treated advanced NSCLC. Gefitinib is tolerable and had favorable adverse events.

show abstract

Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer

Rodriguez¹,

Adelstein²

2011

Head and Neck Cancer

View full text Add to dashboard Cite

Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

Cited by 6 publications

References 49 publications

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer

Contact Info

Product

Resources

About